DelveInsight's "CARVYKTI Market Size, Forecast, and Market Insight Report" highlights the details around CARVYKTI, a ...

The research team, led by Professors Kwong Yok-lam (front right) and Eric Tse Wai-choi (front left), successfully utilises ...

Oncologists are increasingly favoring CAR T-cell therapy’s early-line use in relapsed/refractory multiple myeloma despite ...

Today's Marketplace (TMP) is proud to announce a featured interview with Arcellx, Inc. (NASDAQ: ACLX) Chief Medical Officer Christopher Heery, M.D., and Jessica Clark, DNP, RN, Dean of the College of ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Multiple myeloma is a rare blood cancer of the plasma cells in bone marrow -- the soft, spongy interior of bone where ...

Longtime 95.5 WSB radio host Scott Slade has announced he has been diagnosed with multiple myeloma, a type of blood cancer ...

Plasma cell leukemia (PCL) is a rare disease that may present de novoor secondary to plasma cell myeloma. Advanced disease and extramedullary involvement are common clinical features at presentation.

The full interview can be viewed online here. “Multiple myeloma is a type of cancer that affects plasma cells, which are white blood cells responsible for producing antibodies. These cancerous ...

Groundbreaking research at the Yale Cancer Center offered hope for patients diagnosed with Multiple Myeloma, a type of blood ...

As a BCMA-targeting CAR T-cell therapy, CARVYKTI addresses a high unmet need in relapsed or refractory multiple myeloma patients. With promising clinical efficacy, durable responses, and growing ...